Experts convened to discuss ADC sequencing strategies, biomarker testing infrastructure, and emerging data across cervical, ovarian, and endometrial cancers.
|Videos|November 8, 2017
Dr. Ghamande Discusses GOG/NRG 0265 Study in Cervical Cancer
Author(s)Sharad Ghamande, MD
Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the GOG/NRG-0265 study in cervical cancer.
Advertisement
Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the GOG/NRG-0265 study in cervical cancer.
The phase II GOG/NRG-0265 study sought to identify pre-treatment baseline levels of serum proteins to establish overall survival benefit for patients with persistent or recurrent metastatic carcinoma of the cervix treated with axalimogene filolisbac.
Advertisement
Related to this article
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
PFS was improved only numerically with the use of maintenance dostarlimab vs observation after chemoradiation in high-risk locally advanced cervical cancer.
Six-year GARNET data show durable responses with dostarlimab in dMMR/MSI-H endometrial cancer.
The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.
Neoadjuvant nivolumab yielded a 68.2% clinical complete response rate in patients with resectable mismatch repair–deficient endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
4
Zanubrutinib Plus R-BAP Elicits High Response Rates in Treatment-Naive Mantle Cell Lymphoma
5